Evidence map›Paper›PMID 37872937›Full record

ReviewCureus2023

A Narrative Review on the Efficacy and Safety of Loop Diuretics in Patients With Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction.

Ruth Pius, God-Dowell O Odukudu, Israel Olorundare, Deborah I Makanjuola, Rosemary Komolafe, Chidimma Njoku, Ogheneakpobor E Ubogun, Ramatu Muhammad, Elsie O Osiogo, Caleb Anulaobi

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 3 countries.

Ruth PiusInternal Medicine, Lincoln Medical Centre, Bronx, USA.
God-Dowell O OdukuduInternal Medicine, Delta State University, Abraka, NGA.
Israel OlorundareSurgery, Johns Hopkins University School of Medicine, Baltimore, USA.
Deborah I MakanjuolaPublic Health, University of Alabama at Birmingham, Birmingham, USA.
Rosemary KomolafeClinical Sciences, University of Ilorin, Ilorin, NGA.
Chidimma NjokuInternal Medicine, Gomel State Medical University, Gomel, BLR.
Ogheneakpobor E UbogunInternal Medicine, Delta State University Teaching Hospital, Oghara, NGA.
Ramatu MuhammadPublic Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Elsie O OsiogoInternal Medicine, Ahmadu Bello University Teaching Hospital, Zaria, NGA.
Caleb AnulaobiInternal Medicine/Infectious Diseases, Ekiti State Ministry of Health and Human Services, Ado-Ekiti, NGA.
Johns Hopkins University · USAbia State University · NGAhmadu Bello University Teaching Hospital · NGDelta State University · USDelta State University · NGGomel State Medical University · BYLincoln Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Ilorin · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To date, loop diuretics are the mainstay treatment for decongestion in patients with acute decompensated heart failure (HF). In clinical practice, loop diuretics have also been utilized for patients with chronic HF with reduced and preserved ejection fractions. There is a paucity of quality evidence of the effect of loop diuretics use and dosing on clinical outcomes in HF patients beyond symptomatic relief. In this review, we aimed to summarize recently published data on the use of loop diuretics in patients with HF, focusing on efficacy and safety outcomes in patients with HF with reduced and preserved ejection fraction. We searched EMBASE, PubMed, CINAHL, and the "Web of Science" databases. Cohort studies and randomized controlled trials published after 2018 and written in English were included in this review. Case reports, case series, cross-sectional studies, review articles, commentaries, articles published more than five years ago, and studies involving children were excluded. Results were divided into the efficacy and safety of loop diuretics in HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). A registry-based study included in our review observed a reduced 30-day all-cause mortality in patients with HFrEF receiving loop diuretics compared to those not receiving loop diuretics (HR=0.73; 95% CI=0.57-0.94; p=0.016), but there was no statistically significant association at the 60-day follow-up of the same group of patients. Most studies reviewed showed that the choice of loop diuretics did not influence clinical outcomes such as mortality and HF rehospitalization in patients with HF with reduced and preserved ejection fraction despite differences in oral bioavailability and half-life. Studies have consistently shown that patients with HF who receive a higher dose of loop diuretics are likely to experience a decline in renal function and hypotension, regardless of their type of HF. Discontinuation or reduction of the dose of loop diuretics should be considered in patients with HF after decongestion.

Indexed as

efficacyhfpefhfrefloop diureticssafety

Identifiers

PMID37872937
PMCPMC10590658
OpenAlexW4386946534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.